New commercial model in the works at GSK
Executive Summary
GlaxoSmithKline is jumping on the bandwagon to restructure as the sales environment shifts. CEO Andrew Witty says the company is remodeling its U.S. operations, but did not offer specifics during a third quarter earnings call Oct. 22. The firm continues to take a hit from generic competition in the U.S. and the Avandia (rosiglitazone) controversy (1"The Pink Sheet," June 16, 2008, p. 25)
You may also be interested in...
Hypertensives May Get Class Outcome Labels; Industry Wary Of Broad Efficacy
Two major drug companies with significant hypertension profiles are welcoming the proposed inclusion of class-wide cardiovascular outcomes data in antihypertensive drug labeling - in contrast to other firms that commented on the FDA draft guidance
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.